We are focused on advancing our lead program – an orally bioavailable IL-17 antagonist – through IND-enabling studies and into clinical development for the treatment of psoriasis. Industry reports and early market research indicate strong potential for an efficacious and convenient oral treatment for psoriasis. Enthusiastic responses from prescribing physicians as well as thought leaders in the fields of rheumatology and dermatology highlight the potential for this agent to displace prescriptions of both marketed antibodies as well as oral agents with suboptimal tolerability and efficacy profiles.
We are simultaneously continuing work on our Sanofi-partnered I/O small molecule program. Through disciplined application of our drug discovery capabilities we are seeking to advance one of our discovery programs into preclinical studies by mid-2020.